DUBLIN--(BUSINESS WIRE)--The "Global Eczema Therapeutics Market 2022-2026" report has been added to ResearchAndMarkets.com's offering.
The eczema therapeutics market is poised to grow by $4.36 bn during 2022-2026, accelerating at a CAGR of 9.6% during the forecast period. The report on the eczema therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, challenges, and vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis of the current global market scenario, the latest trends and drivers, and the overall market environment. The market is driven by a strong pipeline landscape.
The eczema therapeutics market analysis includes the indications segment and geographic landscape.
The eczema therapeutics market is segmented as below: By Indications
- Atopic dermatitis
- Contact dermatitis
- Others
By Geographical Landscape
- North America
- Europe
- Asia
- The Rest of the World (ROW)
This study identifies the business strategies as one of the prime reasons driving the eczema therapeutics market growth during the next few years. Also, geopolitical uncertainties and increasing healthcare expenditure will lead to sizable demand in the market.
The report on the eczema therapeutics market covers the following areas:
- Eczema therapeutics market sizing
- Eczema therapeutics market forecast
- Eczema therapeutics market industry analysis
Key Topics Covered:
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Five Forces Analysis
5 Market Segmentation by Indication
6 Customer Landscape
7 Geographic Landscape
8 Drivers, Challenges, and Trends
9 Vendor Landscape
10 Vendor Analysis
11 Appendix
Companies Mentioned
- AbbVie Inc.
- Alliance Pharma Plc
- Amneal Pharmaceuticals Inc.
- AstraZeneca Plc
- Bausch Health Co Inc
- Bayer AG
- Cadila Pharmaceuticals Ltd.
- Eli Lilly and Co.
- Glenmark Pharmaceuticals Ltd
- Incyte Corp.
- LEO Pharma AS
- Lupin Ltd.
- Mayo Foundation for Medical Education and Research
- Merck and Co. Inc.
- Novartis AG
- Pfizer Inc.
- Regeneron Pharmaceuticals Inc.
- Sanofi SA
- Teva Pharmaceutical Industries Ltd.
- Viatris Inc.
For more information about this report visit https://www.researchandmarkets.com/r/sos08p
